Recruiting to Preclinical Alzheimer's Disease Clinical Trials Through Registries

Overview

Journal Alzheimers Dement (N Y)

Date 2017 Apr 26

PMID 28439532

Citations 13

Authors

Joshua D Grill

Affiliations

Soon will be listed here.

Abstract

Participant registries are repositories of individuals who have expressed willingness to learn about studies for which they may be eligible. Registries are increasingly being utilized to improve recruitment to preclinical Alzheimer's disease (AD) clinical trials, which require large screening efforts to identify adequate numbers of participants who meet enrollment criteria. Recruiting to preclinical AD trials from registries is made more efficient through registry collection of data that permits exclusion of those who will not be eligible and identifies individuals most likely to qualify for trials. Such data could include self-reported disease family history or other risk factors, but could also include cognitive, genetic, or biomarker testing outcomes. Few data are available to guide investigators overseeing registries and important ethical questions are likely to arise related to their conduct, especially in registries collecting AD risk information. This article outlines three areas of consideration for registry investigators: informed consent, disclosure, and sponsorship.

Citing Articles

Evaluation of efficiency and effectiveness of different recruitment strategies for the FINGER-NL multidomain lifestyle intervention trial via the Dutch Brain Research Registry.

Waterink L, Sikkes S, Soons L, Beers S, Meijer-Krommenhoek Y, van de Rest O Alzheimers Dement (N Y). 2025; 11(1):e70017.

PMID: 39790861 PMC: 11712179. DOI: 10.1002/trc2.70017.

Ethical issues in genomics research in persons with Alzheimer's Disease/Alzheimer's Disease-related dementia (AD/ADRD): a systematic review.

Yakubu A, Adedeji I, Maduka O, Jegede A, Adebamowo C BMC Med Ethics. 2024; 25(1):138.

PMID: 39587628 PMC: 11587778. DOI: 10.1186/s12910-024-01141-w.

Comparing research attitudes in Down syndrome and non-Down syndrome research decision-makers.

Lu T, Campos P, Leader S, Lee X, Xu H, Doran E Alzheimers Dement (N Y). 2024; 10(3):e12478.

PMID: 39086735 PMC: 11289724. DOI: 10.1002/trc2.12478.

Subjective Cognitive Decline in a Registry Sample: Relation to Psychiatric History, Loneliness, and Personality.

Reynolds G, Manning L, Kirn D, Klein H, Hampton O, Burke Jr O J Prev Alzheimers Dis. 2022; 9(3):435-440.

PMID: 35841244 PMC: 8940594. DOI: 10.14283/jpad.2022.31.

Diversifying Recruitment Registries: Considering Neighborhood Health Metrics.

Grill J, Kind A, Hoang D, Gillen D J Prev Alzheimers Dis. 2022; 9(1):119-125.

PMID: 35098982 PMC: 8903055. DOI: 10.14283/jpad.2021.50.

References

Emanuel E, Wendler D, Grady C . What makes clinical research ethical?. JAMA. 2000; 283(20):2701-11. DOI: 10.1001/jama.283.20.2701. View

Halpern S, Karlawish J, Berlin J . The continuing unethical conduct of underpowered clinical trials. JAMA. 2002; 288(3):358-62. DOI: 10.1001/jama.288.3.358. View

Green M, Peterson S, Baker M, Harper G, Friedman L, Rubinstein W . Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. JAMA. 2004; 292(4):442-52. PMC: 1237120. DOI: 10.1001/jama.292.4.442. View

Harris P, Lane L, Biaggioni I . Clinical research subject recruitment: the Volunteer for Vanderbilt Research Program www.volunteer.mc.vanderbilt.edu. J Am Med Inform Assoc. 2005; 12(6):608-13. PMC: 1294031. DOI: 10.1197/jamia.M1722. View

Wendler D, Pentz R . How does the collection of genetic test results affect research participants?. Am J Med Genet A. 2007; 143A(15):1733-8. DOI: 10.1002/ajmg.a.31823. View

Jenkins J, Calzone K, Dimond E, Liewehr D, Steinberg S, Jourkiv O . Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling. Genet Med. 2007; 9(8):487-95. DOI: 10.1097/gim.0b013e31812e6220. View

Carpenter B, Xiong C, Porensky E, Lee M, Brown P, Coats M . Reaction to a dementia diagnosis in individuals with Alzheimer's disease and mild cognitive impairment. J Am Geriatr Soc. 2008; 56(3):405-12. DOI: 10.1111/j.1532-5415.2007.01600.x. View

Wendler D, Krohmal B, Emanuel E, Grady C . Why patients continue to participate in clinical research. Arch Intern Med. 2008; 168(12):1294-9. DOI: 10.1001/archinte.168.12.1294. View

Marcantonio E, Aneja J, Jones R, Alsop D, Fong T, Crosby G . Maximizing clinical research participation in vulnerable older persons: identification of barriers and motivators. J Am Geriatr Soc. 2008; 56(8):1522-7. PMC: 2562594. DOI: 10.1111/j.1532-5415.2008.01829.x. View

10.

Green R, Roberts J, Cupples L, Relkin N, Whitehouse P, Brown T . Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009; 361(3):245-54. PMC: 2778270. DOI: 10.1056/NEJMoa0809578. View

11.

Resnick S, Sojkova J, Zhou Y, An Y, Ye W, Holt D . Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010; 74(10):807-15. PMC: 2839197. DOI: 10.1212/WNL.0b013e3181d3e3e9. View

12.

Bradbury A, Patrick-Miller L, Fetzer D, Egleston B, Cummings S, Forman A . Genetic counselor opinions of, and experiences with telephone communication of BRCA1/2 test results. Clin Genet. 2010; 79(2):125-31. PMC: 3059740. DOI: 10.1111/j.1399-0004.2010.01540.x. View

13.

Grill J, Karlawish J . Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther. 2010; 2(6):34. PMC: 3031880. DOI: 10.1186/alzrt58. View

14.

Ackerman R, Goldsmith M . Metacognitive regulation of text learning: on screen versus on paper. J Exp Psychol Appl. 2011; 17(1):18-32. DOI: 10.1037/a0022086. View

15.

Sperling R, Aisen P, Beckett L, Bennett D, Craft S, Fagan A . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):280-92. PMC: 3220946. DOI: 10.1016/j.jalz.2011.03.003. View

16.

Karlawish J . Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology. 2011; 77(15):1487-93. PMC: 4561233. DOI: 10.1212/WNL.0b013e318232ac1a. View

17.

Harris P, Scott K, Lebo L, Hassan N, Lightner C, Pulley J . ResearchMatch: a national registry to recruit volunteers for clinical research. Acad Med. 2011; 87(1):66-73. PMC: 3688834. DOI: 10.1097/ACM.0b013e31823ab7d2. View

18.

Rodrigue K, Kennedy K, Devous Sr M, Rieck J, Hebrank A, Diaz-Arrastia R . β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012; 78(6):387-95. PMC: 3280058. DOI: 10.1212/WNL.0b013e318245d295. View

19.

Roberts J, Chen C, Uhlmann W, Green R . Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease. Genet Med. 2012; 14(8):742-8. PMC: 3718049. DOI: 10.1038/gim.2012.37. View

20.

Schneider L . Recruitment methods for United States Alzheimer disease prevention trials. J Nutr Health Aging. 2012; 16(4):331-5. DOI: 10.1007/s12603-012-0011-6. View